SEC Comment Letter for Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464) (ATRA) — May 2, 2023

Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464)
Date: May 2, 2023 · CIK: 0001604464 · Accession: 0000000000-23-004518

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-36548

Date

May 2, 2023

Author

Pascal Touchon

Form

UPLOAD

Company

Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464)

Letter

United States securities and exchange commission logo May 2, 2023 Pascal Touchon President and Chief Executive Officer Atara Biotherapeutics, Inc. 2380 Conejo Spectrum Street Suite 200 Thousand Oaks, CA 91320 Re:Atara Biotherapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed February 8, 2023 File No. 001-36548 Dear Pascal Touchon: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
May 2, 2023
Pascal Touchon
President and Chief Executive Officer
Atara Biotherapeutics, Inc.
2380 Conejo Spectrum Street
Suite 200
Thousand Oaks, CA 91320
Re:Atara Biotherapeutics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2022
Filed February 8, 2023
File No. 001-36548
Dear Pascal Touchon:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io